Investment Thesis
This development-stage medical device company demonstrates promising revenue growth (+63.7% YoY) but faces critical financial distress with zero gross margins, operating losses of -$6.9M on only $704K revenue, and negative operating cash flow of -$3.8M. At the current burn rate, existing cash reserves of $1.4M provide less than 5 months of operational runway, creating severe existential risk without immediate revenue acceleration or external funding.
Strengths
- Revenue growth of 63.7% YoY demonstrates market demand for products/services
- No long-term debt burden provides balance sheet flexibility
- Positive cash position of $1.4M provides near-term operational cushion
Risks
- Zero gross profit margin indicates business model is not generating positive unit economics
- Operating cash burn of -$3.8M annually with estimated 4-5 month cash runway creates imminent liquidity crisis
- Operating expenses of $6.9M exceed revenue by 976%, with no clear path to profitability visible
- Negative free cash flow and inability to self-fund operations requires external capital dependency
- Pre-commercial or early-stage business model with unproven ability to scale profitably
Key Metrics to Watch
- Gross profit margin progression toward breakeven
- Monthly cash burn rate and updated runway assessment
- Revenue growth sustainability and acceleration trajectory
- Operating expense reduction initiatives and efficiency gains
- Funding announcements or capital raises for runway extension
Financial Metrics
Revenue
704.0K
Net Income
-6.9M
EPS (Diluted)
$-0.44
Free Cash Flow
-3.8M
Total Assets
2.7M
Cash
1.4M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
-982.2%
Net Margin
-975.7%
ROE
-649.9%
ROA
-256.6%
FCF Margin
-543.8%
Balance Sheet & Liquidity
Current Ratio
1.19x
Quick Ratio
1.18x
Debt/Equity
0.00x
Debt/Assets
60.5%
Interest Coverage
-493.93x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T08:06:26.393863 |
Data as of: 2025-12-31 |
Powered by Claude AI